SPRYCEL Dasatinib Oral Tablets Patient Information

This document provides patient information for SPRYCEL (dasatinib) oral tablets, including indications, dosage, administration, warnings, and adverse reactions.


SPRYCEL Dasatinib Oral Tablets Patient Information - cover page
Brand
Bristol-Myers Squibb
Category
Other
Document type
User Manual
Language
Chinese
Pages
31
File format
PDF
File size
1 MB
Published
16 October, 2026
Updated
16 October, 2026
MD5 checksum
B33E9FEE161CF74CEBC2E023D29FC5C4

About this manual

This document is the patient information leaflet for SPRYCEL (dasatinib), an oral tablet used to treat certain types of leukemia. It outlines the approved uses for adults with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The text details specific dosing regimens based on the type of leukemia and patient history, such as 100 mg daily for chronic phase CML and 140 mg daily for accelerated phase or Ph+ ALL. This manual is written in Chinese.

What's inside

  • Indications and Usage
  • Dosage and Administration
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Drug Interactions
  • Use in Specific Populations
  • How Supplied

Specifications

Dosage for Chronic Phase CML100 mg once daily
Dosage for Accelerated Phase CML or Ph+ ALL140 mg once daily
Available Strengths20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg

Frequently asked questions

What is the recommended starting dose for chronic phase CML?

The recommended starting dose is 100 mg taken orally once daily.

How should SPRYCEL tablets be taken?

Tablets should be swallowed whole and should not be crushed or sliced. They can be taken with or without food.

What are the most common adverse reactions in newly diagnosed chronic phase CML patients?

The most common adverse reactions include bone marrow suppression, fluid retention, diarrhea, headache, musculoskeletal pain, and rash.

Download PDF (1 MB)